There are four vaccines that are in phase 3 clinical trials in the USA. They are * BioNTech/Pfizer vaccines * Moderna * Johnson & Johnson viral vector vaccine. * Oxford/AstraZeneca viral vector vaccine A fifth vaccine should start US trials in October. * Novavax The two current leaders are Pfizer and Moderna. The CEO of …
The Philadelphia Federal Reserve published results of a survey of 35 economic forecasters on August 14, 2020. They predicted the US economy would expand at an annual rate of 19.1 percent in the third quarter. This was almost double the prediction of 10.6 percent from the last survey. The forecasters expected real GDP to decrease …
Pfizer and BioNTech have a COVID-19 mRNA (messenger RNA) Vaccine candidate in a phase 3 trial. Pfizer will have up to 30,000 participants in phase 3 clinical trial that started in July 2020. As of Aug 20, 2020 they had enrolled more than 11,000 participants. BNT162b2 remains under clinical study and is not currently approved …
Dr. Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security, reports that the first generation of COVID-19 vaccines will give people who have vaccinated a 50% lower chance of getting infected than somebody who hasn’t been vaccinated. US Operation Warp Speed is giving billions to private pharma companies to try to …
Eli Lilly a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities). LY-CoV555, the lead antibody from Lilly’s collaboration with AbCellera, is a neutralizing antibody against SARS-CoV-2, …
The coronavirus is currently changing slowly. There are only about two dozen mutations. There have been many reports of multiple strains of SARS-CoV-2. Virologists use the world strain as a label to the same group of samples. This does not mean they are functionally different. Strain can also refer to viral genotypes that are functionally …
Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner expects that any coronavirus vaccine that proves to be safe and effective will still probably only provide immunity for a limited amount of time, maybe “up to a year,” former Food and Drug Administration Commissioner Dr. Scott Gottlieb …
X-FDA Commissioner Scott Gottlieb and four other experts have published a roadmap to re-opening the US economy from Coronavisus shutdowns. Here Nextbigfuture reviews the details of the next phase. Trigger for Moving to Phase II A state can safely proceed to Phase II when it has achieved all the following: A sustained reduction in cases …
There is reports of 77 different Coronavirus clinical trial applications filed have been China. Other sources talking about 19 clinical trials registered in China. Two weeks ago there were an estimated 30 anti-coronavirus therapies in the pipeline. Researchers in China are launching more systematic tests of these repurposed medicines. Since January 28, scientists have registered …
An Ebola vaccine (rVSV-ZEBOV-GP Ebola vaccine) tested in Africa is 97.5% effective. Only 8.8% (60/679) of the vaccinated rings reported Ebola cases, and only 2.2% (15/679) reported Ebola cases 10 days or more after vaccination.The majority of cases among vaccinated people (76%, 54/71) occurred among high-risk contacts. Only 2 out of 68,279 vaccinated contacts of …
Bill Gates says the biggest risk that we reasonably face is a bioterrorism attack or natural pandemics. Pandemic and Epidemic Risks Relatively average costs for more serious infectious events are high in terms of deaths and costs. One study found the worldwide spread of a serious infectious disease could result in pandemic-related deaths of 700,000 …